Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast

Not Applicable

Completed

• Conditions: Kidney Metastatic Cancer; Rectal Metastatic Cancer; Breast Metastatic Cancer; Colon Metastatic Cancer; GIST Metastatic Cancer
• Interventions: Device: CEUS (Contrast-enhanced ultrasound)

• Registration Number: NCT02666690
• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Brief Summary

RECIST criteria for evaluating tumor response are often inadequate for the evaluation of anti-angiogenic drugs. An evaluation model of tumor perfusion with contrast-enhanced ultrasonography was developed at Gustave Roussy. It assesses the tumor vascular response through the analysis of 7 different parameters. Several studies (four at IGR, involving 117 patients, and a multicenter study involving 400 patients) showed that CEUS allows early evaluation of the effect of anti-angiogenic drugs. Two of these parameters are particularly interesting for the early identification of patients responding (or not) to treatment. Those are area under curve , and area under the wash-out. To further validate the use of these parameters, it is essential to measure and describe the level of their intra-patient variability.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-07
• Primary Completion: 2013-09
• Study Completion: 2013-10
• Study First Submitted: 2015-08-03
• Study First Submitted QC: 2016-01-27
• Study First Posted: 2016-01-28
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-08
• Last Update Posted: 2016-06-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

1. Patient being treated at IGR for metastatic cancer by anti-angiogenic (s) drug (s) in the following indications:

   • Gastrointestinal sarcoma (GIST)
   • Breast Cancers
   • Kidney Cancers
   • Colorectal Cancers
   • Melanoma

   These anti-angiogenic drugs are used alone or in combination: Bevacizumab (Avastin), imatinib (Gleevec), Sorafenib (Nexavar), sunitinib (Sutent), Everolimus (Afinitor) Temsirolimus (Torisel), ... (non exhaustive list).

2. With at least one clearly identified metastatic tumor lesion (and accessible to ultrasound for acquisition 3 minutes without losing the target), measuring more than 2 cm, less than 50% of the volume is necrotic.

   Metastatic lesions are:

   • Liver (30 patients)
   • Or outside the liver (30 patients)

3. Physiological Age: 18-80 years

4. performance status <2

5. Patient information and signature of informed consent

Exclusion Criteria

1. Background known hypersensitivity to sulfur hexafluoride or one of the components,
2. recent history of acute coronary syndrome or unstable ischemic heart disease,
3. Acute heart failure, heart failure stage III or IV, or severe rhythm disorders,
4. uncontrolled hypertension or severe pulmonary hypertension,
5. Right-Left Shunt,
6. Respiratory Distress Syndrome,
7. Patient without vascularized tumor (without contrast enhancement)
8. patient whose antiangiogenic has already started,
9. Pregnant woman likely to be or breastfeeding,
10. Persons deprived of liberty or under guardianship,
11. Unable to submit to medical monitoring of the trial for geographical, social or psychological reasons

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Patients with metastatic cancer treated with anti angiogenics	CEUS (Contrast-enhanced ultrasound)	-

Primary Outcome Measures

Name	Time	Method
Variability of quantitative parameters of Tumor Perfusion Evaluated With Ultrasound Contrast	Assessed 30 days after inclusion	Demonstrate that for the hepatic metastatic sites and for non hepatic metastatic sites the variability of the measured quantitative parameters on two different perfusion curves is less than 30%

Trial Locations

Locations (1)

Gustave Roussy Cancer Campus Grand Paris; 🇫🇷 Villejuif, Val de Marne, France